

Serial No.: 09/936,377  
Docket No.: BM45379

In the Claims:

Claims 1-24 (Cancelled)

25. (Previously Presented): An isolated polypeptide comprising a member selected from the group consisting of
  - (a) the amino acid sequence SEQ ID NO:2; and
  - (b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.
26. (Cancelled)
27. (Previously Presented): The isolated polypeptide of claim 25, wherein the polypeptide is according to (a).
28. (Cancelled)
29. (Previously Presented): The isolated polypeptide of claim 25, wherein the polypeptide is according to (b).
30. (Cancelled)
31. (Previously Presented): The isolated polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

Serial No.: 09/936,377  
Docket No.: BM45379

32. (Previously Presented): The isolated polypeptide of Claim 25 wherein the isolated polypeptide consists of SEQ ID NO:2.

Claims 33-34 (Cancelled)

35. (Previously Presented): A fusion protein comprising the isolated polypeptide of Claim 25.

Claims 36-39 (Cancelled)

40. (Previously Presented): An immunogenic composition comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

41. (Previously Presented): The immunogenic composition of Claim 40, wherein the immunogenic composition comprises at least one other *Neisseria meningitidis* antigen.

42. (Cancelled)

43. (Previously Presented): A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 25.

Claims 44-46 (Cancelled)

47. (Previously Presented): The isolated polypeptide of Claim 25, wherein the isolated polypeptide is a recombinant polypeptide.

48. (Previously Presented): A fusion protein comprising the isolated polypeptide of Claim 27.

Serial No.: 09/936,377  
Docket No.: BM45379

49. (Previously Presented): An immunogenic composition comprising the isolated polypeptide of Claim 27.
50. (Previously Presented): A fusion protein comprising the isolated polypeptide of Claim 29.
51. (Previously Presented): An immunogenic composition comprising the isolated polypeptide of Claim 29.
52. (New): The isolated polypeptide of claim 25, wherein the polypeptide is a recombinant polypeptide.
53. (New): A fusion protein comprising the isolated polypeptide of Claim 52.
54. (New): An immunogenic composition comprising the isolated polypeptide of Claim 52.
55. (New): The isolated polypeptide of claim 27, wherein the polypeptide is a recombinant polypeptide.
56. (New): The isolated polypeptide of claim 29, wherein the polypeptide is a recombinant polypeptide.

AUG 13 2004 9:03 AM FR

TO 917038729307

P.06

PAGE 6/10 \* RCVD AT 8/13/2004 9:08:18 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-1/0 \* DNI:8729307 \* CSID: \* DURATION (mm:ss):03-12